Dr. Nozha Boujemaa will oversee the company scientific vision as well as strategies for innovation, development and academic and industrial partnerships for iBiopsy®, the Median Technologies Imaging Phenomics platform.Read more
News & events
Median will be exhibiting at ASCO 2019 from May 31 to June 4 in Chicago, IL. Please stop by booth #6102 to learn more about our breakthrough imaging solutions and services for oncology clinical trials and our Imaging Phenomics platform iBiopsy®. Happy to see you there!Visit conference website
iBiopsy® for Precision Medicine
Check out our paper published in the European Medical Journal on December 13, 2018 in order to educate the oncology specialists across Europe and the US as to the high-throughput artificial intelligence powered image-base phenotyping platform, iBiopsy® -> http://viewer.zmags.com/publication/647c38a3#/647c38a3/50
A high-throughput artificial intelligence-powered image-based phenotyping platform, iBiopsy® (Median Technologies, Valbonne, France), which aims to improve precision medicine, is discussed in the presented review. The article introduces novel concepts, including high-throughput, fully automated imaging biomarker extraction; unsupervised predictive learning; large-scale content-based image-based similarity search; the use of large-scale clinical data registries; and cloud-based big data analytics to the problems of disease subtyping and treatment planning. Unlike electronic health record-based approaches, which lack the detailed radiological, pathological, genomic, and molecular data necessary for accurate prediction, iBiopsy® generates unique signatures as fingerprints of disease and tumor subtypes from target images. These signatures are then merged with any additional omics data and matched against a large-scale reference registry of deeply phenotyped patients. Initial applications targeted include hepatocellular carcinoma and other chronic liver diseases, such as nonalcoholic steatohepatitis. This new disruptive technology is expected to lead to the identification of appropriate therapies targeting specific molecular pathways involved in the detected phenotypes to bring personalised treatment to patients, taking into account individual biological variability, which is the principal aim of precision medicine.